BioCentury
ARTICLE | Clinical News

Suvorexant regulatory update

August 11, 2014 7:00 AM UTC

Merck disclosed in its 2Q14 financial results that FDA assigned a PDUFA date of Aug. 14 for a resubmitted application for once-daily suvorexant to treat insomnia. In July 2013, FDA issued a complete r...